Great Novel Therapeutics Biotech & Medicals (TPEX:7427)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
40.10
-0.80 (-1.96%)
Apr 29, 2026, 1:58 PM CST

TPEX:7427 Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-97.47-104.92-61-67.13-35.86
Upgrade
Depreciation & Amortization
7.686.94.281.761.44
Upgrade
Other Amortization
-0.040.070.060.06
Upgrade
Loss (Gain) From Sale of Assets
---0.12--
Upgrade
Stock-Based Compensation
11.1614.9711.294.913.66
Upgrade
Other Operating Activities
0.10.130.09-0.01-0.03
Upgrade
Change in Accounts Receivable
0.65-0.62-0.09--0.04
Upgrade
Change in Inventory
-4.283.15-6.16--
Upgrade
Change in Accounts Payable
-2.956.611.05--
Upgrade
Change in Other Net Operating Assets
-2.44-3.09-4.4-16.76-3.15
Upgrade
Operating Cash Flow
-87.56-76.85-54.99-77.17-33.92
Upgrade
Capital Expenditures
-0.28-2.11-2.93-0.05-0.04
Upgrade
Sale of Property, Plant & Equipment
--0.12--
Upgrade
Sale (Purchase) of Intangibles
-3.21-1.36-16.29-1.18-27.97
Upgrade
Investment in Securities
10-130.7-160.5-74.19-62.32
Upgrade
Other Investing Activities
2.860.68-3.18-2.45-
Upgrade
Investing Cash Flow
9.37-133.49-182.78-77.85-90.32
Upgrade
Long-Term Debt Repaid
-3-3-1.25--
Upgrade
Net Debt Issued (Repaid)
-3-3-1.25--
Upgrade
Issuance of Common Stock
0.94188.84307.49203.31120
Upgrade
Repurchase of Common Stock
-44.97----
Upgrade
Financing Cash Flow
-47.03185.84306.24203.31120
Upgrade
Net Cash Flow
-125.22-24.4968.4748.29-4.24
Upgrade
Free Cash Flow
-87.84-78.96-57.92-77.21-33.96
Upgrade
Free Cash Flow Margin
-7289.46%-4685.82%-1194.21%-14298.70%-5389.68%
Upgrade
Free Cash Flow Per Share
-2.04-1.92-1.60-3.20-1.61
Upgrade
Levered Free Cash Flow
-63.66-53.21-48.79-50.61-29.53
Upgrade
Unlevered Free Cash Flow
-63.6-53.14-48.73-50.61-29.53
Upgrade
Change in Working Capital
-9.036.04-9.6-16.76-3.19
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.